EGF樣域蛋白7(EGFL7)重組蛋白
Recombinant EGF Like Domain Protein, Multiple 7 (EGFL7)
ZNEU1; MEGF7; Zneu1; Vascular endothelial statin; EGF Like Domain Containing 7; Epidermal growth factor-like protein 7; Multiple epidermal growth factor-like domains protein 7
- 編號URPL643Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預測分子量31.2kDa
- 實際分子量31kDa(差異分析請參閱說明書)
- 片段與標簽Glu22~Leu275 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose .
- 性狀凍干粉
- 純度> 90%
- 等電點7.9
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 550 ¥ 1374 ¥ 2748 ¥ 8244 ¥ 20610
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPL643Mu01 | EGF樣域蛋白7(EGFL7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPL643Mu02 | EGF樣域蛋白7(EGFL7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAL643Mu02 | EGF樣域蛋白7(EGFL7)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAL643Mu01 | EGF樣域蛋白7(EGFL7)多克隆抗體 | WB; IHC |
| USEL643Mu | EGF樣域蛋白7(EGFL7)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULML643Mu | EGF樣域蛋白7(EGFL7)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Scientific Reports | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab [PMC5443778] |
| Scientific Reports | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. [pubmed:28539619] |
| International Journal of Clinical and Experimental Pathology | EGF like domain multiple 7 regulates the migration and invasion of prostate cancer cells [ISSN:1936-2625] |
| Cancer Drug Resist | MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy [] |
留言咨詢
